SPDR S&P 500 ETF Trust ( $SPY ) has fallen by 2.04% in the past week. It has experienced a 5-day net outflow of $11.01 billion.
This is due, in part, to market sentiment on some of the ETF’s largest holdings. For example:
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade SPY- Nvidia Corporation stayed at the center of the AI trade as analysts at Tigress Financial boosted their price target to $360 and reiterated a Buy, citing record Q4 FY26 revenue of $68.1 billion, explosive data-center growth, and rapid uptake of its Blackwell and upcoming Vera Rubin GPU platforms. Despite U.S. moves to tighten AI chip exports and security-driven office closures in the Middle East, Wall Street still rates Nvidia a Strong Buy, with an average target near $272 implying about 50% upside and investors steadily adding the stock to portfolios.
- Apple Inc drew renewed optimism after Wedbush’s Daniel Ives and other analysts raised or reaffirmed bullish targets, with Street‑high calls up to $350 as the company rolled out AI‑focused M5‑based MacBook Air, Pro and new entry‑level MacBook Neo models, plus an iPhone 17e and updated iPads and displays. Apple is pushing higher pricing across Macs to offset memory costs while using stronger on‑device AI performance to attract first‑time Mac buyers, and the shares carry a Moderate Buy rating with an average target around $306, implying mid‑teens upside despite recent underperformance.
- Microsoft shares slipped as investors reacted coolly to the reveal of “Project Helix,” a next‑generation Xbox planned to run both Xbox and PC games using AMD chips but still lacking clear specs, pricing and launch timing, with 2027 the current expectation. At the same time, heavy AI and cloud spending—capex jumping about 66% year over year to $37.5 billion and longer‑term plans for up to $185 billion—has pressured sentiment even as Azure grows strongly and Wall Street maintains a Strong Buy view, with average price targets near $594 and bullish scenarios close to $680 suggesting hefty upside for patient investors.